← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT03561376

Zinc Oxide Versus Petrolatum Following Skin Surgery

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Surgical Incision
Sponsor Melissa Pugliano-Mauro
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-09-01
Completion 2026-09-30
Interventions
Topical zinc oxide vs. petrolatum post-surgical scars

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).

Eligibility Criteria

Inclusion Criteria: 1. ≥ 18 years of age 2. Linear closure, non-scalp site 3. ≥ 4.5 cm in length (final incision/closure length) 4. End to end symmetry (surgical site is not grossly asymmetric from end to end) 5. Grossly uninfected site Exclusion Criteria: 1. ≤ 18 years 2. Visibly asymmetric linear scar 3. Grossly infected surgical site 4. History of allergy to topical zinc oxide

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}